Metabolic syndrome

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 1, 2014, Pages 1-23

  Samson, Susan L ^a   Garber, Alan J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular risk; Diabetes risk; Dyslipidemia; Hypertension; Metabolic syndrome; National Cholesterol Education Program Adult Treatment Panel III; Obesity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY PROGRAM; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INTERNATIONAL COOPERATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; RISK REDUCTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; CLASSIFICATION;

HUMANS; METABOLIC SYNDROME X;

EID: 84896840279     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.09.009     Document Type: Review

References (130)

1. Rossner S. Eskil Kylin (1885-1974). Obes Rev 2009, 10:362.
2. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4(1):20-34.
3. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 2012, 49(2):89-95.
4. Haller H. Epidemiology and associated risk factors of hyperlipoproteinemia. ZGesamte Inn Med 1977, 32(8):124-128. [in German].
5. Singer P. Diagnosis of primary hyperlipoproteinemias. ZGesamte Inn Med 1977, 32(9):129-133. [in German].
6. Phillips G.B. Sex hormones, risk factors and cardiovascular disease. Am J Med 1978, 65(1):7-11.
7. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
8. WHO obesity and overweight fact sheet no. 311. Available at:. Accessed October 23, 2013. http://www.who.int/mediacentre/factsheets/fs311/en/.
9. Hossain P., Kawar B., El N.M. Obesity and diabetes in the developing world-a growing challenge. NEngl J Med 2007, 356(3):213-215.
10. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-553.
11. Balkau B., Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16(5):442-443.
12. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003, 9(3):237-252.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486-2497.
14. Available at:. Accessed October 23, 2013. http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf.
15. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004, 24(2):e13-e18.
16. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23(5):469-480.
17. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
18. Marcovecchio M.L., Chiarelli F. Metabolic syndrome in youth: chimera or useful concept?. Curr Diab Rep 2013, 13(1):56-62.
19. Cook S., Weitzman M., Auinger P., et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003, 157(8):821-827.
20. Zimmet P., Alberti K.G., Kaufman F., et al. The metabolic syndrome in children and adolescents-an IDF consensus report. Pediatr Diabetes 2007, 8(5):299-306.
21. Beltran-Sanchez H., Harhay M.O., Harhay M.M., et al. Prevalence and trends of metabolic syndrome in the adult US population, 1999-2010. JAm Coll Cardiol 2013, 62:697-703.
22. Gao W. Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk?. Int J Obes (Lond) 2008, 32(5):757-762.
23. Pandit K., Goswami S., Ghosh S., et al. Metabolic syndrome in South Asians. Indian J Endocrinol Metab 2012, 16(1):44-55.
24. Mabry R.M., Reeves M.M., Eakin E.G., et al. Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review. Diabet Med 2010, 27(5):593-597.
25. Lee S.R., Cha M.J., Kang D.Y., et al. Increased prevalence of metabolic syndrome among hypertensive population: ten years' trend of the Korean National Health and Nutrition Examination Survey. Int J Cardiol 2013, 166(3):633-639.
26. Unno M., Furusyo N., Mukae H., et al. The utility of visceral fat level by bioelectrical impedance analysis in the screening of metabolic syndrome-the results of the Kyushu and Okinawa Population Study (KOPS). JAtheroscler Thromb 2012, 19(5):462-470.
27. Gu D., Reynolds K., Wu X., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005, 365(9468):1398-1405.
28. Wilson P.W., D'Agostino R.B., Parise H., et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112(20):3066-3072.
29. Scuteri A., Najjar S.S., Morrell C.H., et al. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005, 28(4):882-887.
30. Sattar N., McConnachie A., Shaper A.G., et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371(9628):1927-1935.
31. Liu M., Wang J., Jiang B., et al. Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001-2010. PLoS One 2013, 8(6):e66233.
32. Cook S., Auinger P., Li C., et al. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. JPediatr 2008, 152(2):165-170.
33. Monzani A., Rapa A., Fuiano N., et al. Metabolic syndrome is strictly associated with parental obesity beginning from childhood. Clin Endocrinol (Oxf) 2013, [Epub ahead of print].
34. Randeva H.S., Tan B.K., Weickert M.O., et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012, 33(5):812-841.
35. Apridonidze T., Essah P.A., Iuorno M.J., et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. JClin Endocrinol Metab 2005, 90(4):1929-1935.
36. Glueck C.J., Papanna R., Wang P., et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003, 52(7):908-915.
37. Moran L.J., Misso M.L., Wild R.A., et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010, 16(4):347-363.
38. Carmina E., Napoli N., Longo R.A., et al. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006, 154(1):141-145.
39. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19(1):41-47.
40. Gutierrez A.D., Balasubramanyam A. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine 2012, 41(1):1-10.
41. Krishnan S., Schouten J.T., Atkinson B., et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. JAcquir Immune Defic Syndr 2012, 61(3):381-389.
42. Samaras K., Wand H., Law M., et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30(1):113-119.
43. Alencastro P.R., Wolff F.H., Oliveira R.R., et al. Metabolic syndrome and population attributable risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and AHA/NHLBI definitions. AIDS Res Ther 2012, 9(1):29.
44. Freitas P., Carvalho D., Souto S., et al. Impact of lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. BMC Infect Dis 2011, 11:246.
45. Verhelst J., Mattsson A.F., Luger A., et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 2011, 165(6):881-889.
46. Attanasio A.F., Mo D., Erfurth E.M., et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. JClin Endocrinol Metab 2010, 95(1):74-81.
47. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter?. Circulation 2007, 115(13):1806-1810.
48. Boronat M., Saavedra P., Varillas V.F., et al. Differences in traditional and emerging cardiovascular risk factors of subjects discordantly classified by metabolic syndrome definitions of the International Diabetes Federation and the National Cholesterol Education Program. Nutr Metab Cardiovasc Dis 2009, 19(6):417-422.
49. Eddy D.M., Schlessinger L., Heikes K. The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes (Lond) 2008, 32(Suppl 2):S5-S10.
50. Fedorowski A., Burri P., Hulthen L., et al. The metabolic syndrome and risk of myocardial infarction in familial hypertension (hypertension heredity in Malmö evaluation study). JHypertens 2009, 27(1):109-117.
51. Milionis H.J., Kostapanos M.S., Liberopoulos E.N., et al. Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Int J Clin Pract 2007, 61(4):545-551.
52. Nilsson P.M., Engstrom G., Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects-a population-based study comparing three different definitions. Diabet Med 2007, 24(5):464-472.
53. Jeppesen J., Hansen T.W., Rasmussen S., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. JAm Coll Cardiol 2007, 49(21):2112-2119.
54. Wilson P.W., Meigs J.B. Cardiometabolic risk: a Framingham perspective. Int J Obes (Lond) 2008, 32(Suppl 2):S17-S20.
55. Eberly L.E., Prineas R., Cohen J.D., et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006, 29(1):123-130.
56. Cull C.A., Jensen C.C., Retnakaran R., et al. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007, 116(19):2119-2126.
57. Bruno G., Merletti F., Biggeri A., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004, 27(11):2689-2694.
58. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005, 48(9):1684-1699.
59. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48(5):937-942.
60. Ford E.S., Schulze M.B., Pischon T., et al. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol 2008, 7:35.
61. Ford E.S., Li C., Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008, 31(9):1898-1904.
62. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108(4):414-419.
63. Wannamethee S.G., Shaper A.G., Lennon L., et al. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005, 165(22):2644-2650.
64. Cameron A.J., Magliano D.J., Zimmet P.Z., et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. JIntern Med 2008, 264(2):177-186.
65. Krawczyk M., Bonfrate L., Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010, 24(5):695-708.
66. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51(5):1820-1832.
67. Smits M.M., Ioannou G.N., Boyko E.J., et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. JGastroenterol Hepatol 2013, 28(4):664-670.
68. Castro-Martinez M.G., Banderas-Lares D.Z., Ramirez-Martinez J.C., et al. Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir 2012, 80(2):128-133.
69. Caballeria L., Pera G., Rodriguez L., et al. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. Eur J Gastroenterol Hepatol 2012, 24(9):1007-1011.
70. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. NEngl J Med 2003, 348(17):1625-1638.
71. Gilbert C.A., Slingerland J.M. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med 2013, 64:45-57.
72. Giovannucci E., Harlan D.M., Archer M.C., et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010, 60(4):207-221.
73. Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 2008, 31(7):1283-1291.
74. Bremer A.A., Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. JObes 2013, 2013:393192.
75. Fox C.S., Massaro J.M., Hoffmann U., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116(1):39-48.
76. Neeland I.J., Ayers C.R., Rohatgi A.K., et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 2012, 21:E439-E447.
77. Bergman R.N., Kim S.P., Catalano K.J., et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006, 14(Suppl 1):16S-19S.
78. Bergman R.N., Kim S.P., Hsu I.R., et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 2007, 120(2Suppl 1):S3-S8.
79. Klop B., Elte J.W., Cabezas M.C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013, 5(4):1218-1240.
80. Nikolic D., Katsiki N., Montalto G., et al. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013, 5(3):928-948.
81. Subramanian S., Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta 2012, 1821(5):819-825.
82. Gupta A., Gupta V. Metabolic syndrome: what are the risks for humans?. Biosci Trends 2010, 4(5):204-212.
83. Reaven G.M. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. JClin Hypertens (Greenwich ) 2011, 13(4):238-243.
84. Andreassi M.G. Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction. Mutat Res 2009, 667(1-2):35-43.
85. Landsberg L., Aronne L.J., Beilin L.J., et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment-a position paper of the Obesity Society and the American Society of Hypertension. Obesity (Silver Spring) 2013, 21(1):8-24.
86. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. JClin Endocrinol Metab 2004, 89(6):2548-2556.
87. Matsuzawa Y., Funahashi T., Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. JAtheroscler Thromb 2011, 18(8):629-639.
88. West M. Dead adipocytes and metabolic dysfunction: recent progress. Curr Opin Endocrinol Diabetes Obes 2009, 16(2):178-182.
89. Cinti S., Mitchell G., Barbatelli G., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. JLipid Res 2005, 46(11):2347-2355.
90. Semenkovich C.F. Insulin resistance and atherosclerosis. JClin Invest 2006, 116(7):1813-1822.
91. Lusis A.J., Attie A.D., Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 2008, 9(11):819-830.
92. Phillips C.M. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013, 14:219-227.
93. O'Connell J., Lynch L., Cawood T.J., et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 2010, 5(4):e9997.
94. O'Connell J., Lynch L., Hogan A., et al. Preadipocyte factor-1 is associated withmetabolic profile in severe obesity. JClin Endocrinol Metab 2011, 96(4):E680-E684.
95. Povel C.M., Boer J.M., Reiling E., et al. Genetic variants and the metabolic syndrome: a systematic review. Obes Rev 2011, 12(11):952-967.
96. Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia 2008, 51(10):1771-1780.
97. Ingelsson E., Langenberg C., Hivert M.F., et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans. Diabetes 2010, 59:1266-1275.
98. Lyssenko V., Lupi R., Marchetti P., et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. JClin Invest 2007, 117(8):2155-2163.
99. Florez J.C., Jablonski K.A., Bayley N., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. NEngl J Med 2006, 355(3):241-250.
100. Phillips C.M., Goumidi L., Bertrais S., et al. Dietary saturated fat, gender and genetic variation at the TCF7L2 locus predict the development of metabolic syndrome. JNutr Biochem 2012, 23(3):239-244.
101. Warodomwichit D., Arnett D.K., Kabagambe E.K., et al. Polyunsaturated fatty acids modulate the effect of TCF7L2 gene variants on postprandial lipemia. JNutr 2009, 139(3):439-446.
102. Loos R.J., Rankinen T. Gene-diet interactions on body weight changes. JAm Diet Assoc 2005, 105(5 Suppl 1):S29-S34.
103. Loos R.J., Lindgren C.M., Li S., et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40(6):768-775.
104. Loos R.J., Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev 2008, 9(3):246-250.
105. Frayling T.M., Timpson N.J., Weedon M.N., et al. Acommon variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316(5826):889-894.
106. Scuteri A., Sanna S., Chen W.M., et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 2007, 3(7):e115.
107. Kooner J.S., Chambers J.C., Aguilar-Salinas C.A., et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet 2008, 40(2):149-151.
108. Grundy S.M., Hansen B., Smith S.C., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004, 24(2):e19-e24.
109. Yamaoka K., Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med 2012, 10:138.
110. Orchard T.J., Temprosa M., Barrett-Connor E., et al. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 2013, 30(1):46-55.
111. Kramer M.K., Kriska A.M., Venditti E.M., et al. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med 2009, 37(6):505-511.
112. Perreault L., Pan Q., Mather K.J., et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012, 379(9833):2243-2251.
113. Potenza M.V., Mechanick J.I. The metabolic syndrome: definition, global impact, and pathophysiology. Nutr Clin Pract 2009, 24(5):560-577.
114. Ridker P.M., Pradhan A., MacFadyen J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380(9841):565-571.
115. Gotto A.M., Moon J.E. Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol 2013, 10:560-570.
116. Boekholdt S.M., Arsenault B.J., Hovingh G.K., et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 2013, 128:1504-1512.
117. Clofibrate and niacin in coronary heart disease. JAMA 1975, 231(4):360-381.
118. AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011, 161(3):538-543.
119. Guyton J.R., Slee A.E., Anderson T., et al. Relationship of lipoproteins to cardiovascular events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Trial. JAm Coll Cardiol 2013, [Epub ahead of print].
120. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34(17):1279-1291.
121. Ginsberg H.N., Bonds D.E., Lovato L.C., et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99(12A):56i-67i.
122. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362(17):1563-1574.
123. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. NEngl J Med 1999, 341(6):410-418.
124. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
125. Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374(9702):1677-1686.
126. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEngl J Med 2002, 346(6):393-403.
127. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28(9):2289-2304.
128. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006, 97(2A):3A-11A.
129. Simmons R.K., Alberti K.G., Gale E.A., et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010, 53(4):600-605.
130. Kohli P., Greenland P. Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 2006, 295(7):819-821.